Claims for Patent: 10,213,409

Summary for Patent: 10,213,409

Title:	Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
Abstract:	The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
Inventor(s):	Chaplin; Jason Hugh (Thornbury, AU), Gill; Gurmit Sing (Craigieburn, AU), Grobelny; Damian Wojciech (Watsonia North, AU), Flynn; Bernard Luke (Vermont, AU), Kremmidiotis; Gabriel (Flagstaff Hill, AU)
Assignee:	BIONOMICS LIMITED (Thebarton, AU)
Application Number:	15/141,170
Patent Claims:	1. A combination comprising a compound of formula (I) ##STR00107## or a salt thereof, wherein X represents O, S, SO, SO.sub.2, Se, SeO, SeO.sub.2 or NR where R is selected from H, O, optionally substituted acyl, optionally substituted alkenyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, and optionally substituted sulfonyl; R.sup.1A and R.sup.1B each independently represents H, carboxy, cyano, dihalomethoxy, halogen, hydroxy, nitro, pentahaloethyl, phosphorylamino, phosphono, phosphinyl, sulfo, trihaloethenyl, trihalomethanethio, trihalomethoxy, trihalomethyl, optionally substituted acyl, optionally substituted acylamino, optionally substituted acylimino, optionally substituted acyliminoxy, optionally substituted acyloxy, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted alkenyl, optionally substituted alkenyloxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted aminoacyloxy, optionally substituted aminosulfonyl, optionally substituted aminothioacyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted oxyacyl, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted oxyacylimino, optionally substituted oxysulfinylamino, optionally substituted oxysulfonylamino, optionally substituted oxythioacyl, optionally substituted oxythioacyloxy, optionally substituted sulfinyl, optionally substituted sulfinylamino, optionally substituted sulfonyl, optionally substituted sulphonylamino, optionally substituted thio, optionally substituted thioacyl, optionally substituted thioacylamino, or R.sup.1A and R.sup.1B together form an optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloalkenyl; R.sup.1C represents C.sub.1-3 alkoxy, C.sub.1-3 alkylthio, C.sub.1-3 alkylamino, or C.sub.1-3 dialkylamino; R.sup.1D represents hydroxy, amino, or phosphate ester; L represents C.dbd.O, O, S, SO, SO.sub.2, Se, SeO, SeO.sub.2, C.dbd.NZ', or NR' where Z' is H, optionally substituted alkyl, optionally substituted aryl or optionally substituted amino; and where R' is selected from H, O, optionally substituted acyl, optionally substituted alkenyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or optionally substituted sulfonyl; R.sup.2A-R.sup.2E each independently represents H, carboxy, cyano, dihalomethoxy, halogen, hydroxy, nitro, pentahaloethyl, phosphorylamino, phosphono, phosphinyl, sulfo, trihaloethenyl, trihalomethanethio, trihalomethoxy, trihalomethyl, optionally substituted acyl, optionally substituted acylamino, optionally substituted acylimino, optionally substituted acyliminoxy, optionally substituted acyloxy, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted alkenyl, optionally substituted alkenyloxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted aminoacyloxy, optionally substituted aminosulfonyl, optionally substituted aminothioacyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted oxyacyl, optionally substituted oxyacylamino, optionally substituted oxyacylimino, optionally substituted oxyacyloxy, optionally substituted oxysulfinylamino, optionally substituted oxysulfonylamino, optionally substituted oxythioacyl, optionally substituted oxythioacyloxy, optionally substituted sulfinyl, optionally substituted sulfinylamino, optionally substituted sulfonyl, optionally substituted sulphonylamino, optionally substituted thio, optionally substituted thioacyl, optionally substituted thioacylamino, or optionally substituted thioacyloxy; or any of R.sup.2A and R.sup.2B, R.sup.2B and R.sup.2C, R.sup.2C and R.sup.2D, and R.sup.2D and R.sup.2E, together form an optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloalkenyl; and Q represents C.sub.1-4 alkyl, and, at least one further compound that is cytotoxic. 2. The combination according to claim 1 wherein the compound of formula (I) is a compound of formula (Ia) ##STR00108## or a salt thereof, wherein X represents O, S, SO, SO.sub.2, Se, SeO, SeO.sub.2 or NR where R is selected from H, O, optionally substituted acyl, optionally substituted alkenyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, and optionally substituted sulfonyl; R.sup.1A and R.sup.1B each independently represents H, carboxy, cyano, dihalomethoxy, halogen, hydroxy, nitro, pentahaloethyl, phosphorylamino, phosphono, phosphinyl, sulfo, trihaloethenyl, trihalomethanethio, trihalomethoxy, trihalomethyl, optionally substituted acyl, optionally substituted acylamino, optionally substituted acylimino, optionally substituted acyliminoxy, optionally substituted acyloxy, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted alkenyl, optionally substituted alkenyloxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted aminoacyloxy, optionally substituted aminosulfonyl, optionally substituted aminothioacyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted oxyacyl, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted oxyacylimino, optionally substituted oxysulfinylamino, optionally substituted oxysulfonylamino, optionally substituted oxythioacyl, optionally substituted oxythioacyloxy, optionally substituted sulfinyl, optionally substituted sulfinylamino, optionally substituted sulfonyl, optionally substituted sulphonylamino, optionally substituted thio, optionally substituted thioacyl, optionally substituted thioacylamino, or R.sup.1A and R.sup.1B together form an optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloalkenyl; R.sup.1C represents C.sub.1-3 alkoxy, C.sub.1-3 alkylthio, C.sub.1-3 alkylamino, or C.sub.1-3 dialkylamino; R.sup.1D represents hydroxy, amino, or phosphate ester; R.sup.2A and R.sup.2E independently represents H, carboxy, cyano, dihalomethoxy, halogen, hydroxy, nitro, pentahaloethyl, phosphorylamino, phosphono, phosphinyl, sulfo, trihaloethenyl, trihalomethanethio, trihalomethoxy, trihalomethyl, optionally substituted acyl, optionally substituted acylamino, optionally substituted acylimino, optionally substituted acyliminoxy, optionally substituted acyloxy, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted alkenyl, optionally substituted alkenyloxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted aminoacyloxy, optionally substituted aminosulfonyl, optionally substituted aminothioacyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted oxyacyl, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted oxyacylimino, optionally substituted oxysulfinylamino, optionally substituted oxysulfonylamino, optionally substituted oxythioacyl, optionally substituted oxythioacyloxy, optionally substituted sulfinyl, optionally substituted sulfinylamino, optionally substituted sulfonyl, optionally substituted sulphonylamino, optionally substituted thio, optionally substituted thioacyl, optionally substituted thioacylamino, or optionally substituted thioacyloxy; and Q represents C.sub.1-4 alkyl. 3. The combination according to claim 2 wherein R.sup.1A, R.sup.1B, R.sup.2A and R.sup.2E represent H. 4. The combination according to claim 1 wherein the compound of formula (I) is a compound of formula (Ib) ##STR00109## or a salt thereof, wherein X represents O, S, SO, SO.sub.2, Se, SeO, SeO.sub.2 or NR where R is selected from H, O, optionally substituted acyl, optionally substituted alkenyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, and optionally substituted sulfonyl; R.sup.1C represents C.sub.1-3 alkoxy; R.sup.1D represents hydroxy, amino, or phosphate ester; and Q represents C.sub.1-4 alkyl. 5. The combination according to claim 1 wherein the compound of formula (I) is a compound of formula (II) ##STR00110## or a salt thereof, wherein R.sup.1A and R.sup.1B each independently represents H, carboxy, cyano, dihalomethoxy, halogen, hydroxy, nitro, pentahaloethyl, phosphorylamino, phosphono, phosphinyl, sulfo, trihaloethenyl, trihalomethanethio, trihalomethoxy, trihalomethyl, optionally substituted acyl, optionally substituted acylamino, optionally substituted acylimino, optionally substituted acyliminoxy, optionally substituted acyloxy, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted alkenyl, optionally substituted alkenyloxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted aminoacyloxy, optionally substituted aminosulfonyl, optionally substituted aminothioacyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted oxyacyl, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted oxyacylimino, optionally substituted oxysulfinylamino, optionally substituted oxysulfonylamino, optionally substituted oxythioacyl, optionally substituted oxythioacyloxy, optionally substituted sulfinyl, optionally substituted sulfinylamino, optionally substituted sulfonyl, optionally substituted sulphonylamino, optionally substituted thio, optionally substituted thioacyl, optionally substituted thioacylamino, or R.sup.1A and R.sup.1B together form an optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloalkenyl; R.sup.1C represents C.sub.1-3 alkoxy, C.sub.1-3 alkylthio, C.sub.1-3 alkylamino, or C.sub.1-3 dialkylamino; R.sup.1D represents hydroxy, amino, or phosphate ester; L represents C.dbd.O, O, S, SO, SO.sub.2, Se, SeO, SeO.sub.2, C.dbd.NZ', or NR' where Z' is H, optionally substituted alkyl, optionally substituted aryl or optionally substituted amino; and where R' is selected from H, O, optionally substituted acyl, optionally substituted alkenyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or optionally substituted sulfonyl; R.sup.2A-R.sup.2E each independently represents H, carboxy, cyano, dihalomethoxy, halogen, hydroxy, nitro, pentahaloethyl, phosphorylamino, phosphono, phosphinyl, sulfo, trihaloethenyl, trihalomethanethio, trihalomethoxy, trihalomethyl, optionally substituted acyl, optionally substituted acylamino, optionally substituted acylimino, optionally substituted acyliminoxy, optionally substituted acyloxy, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted alkenyl, optionally substituted alkenyloxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted aminoacyloxy, optionally substituted aminosulfonyl, optionally substituted aminothioacyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted oxyacyl, optionally substituted oxyacylamino, optionally substituted oxyacylimino, optionally substituted oxyacyloxy, optionally substituted oxysulfinylamino, optionally substituted oxysulfonylamino, optionally substituted oxythioacyl, optionally substituted oxythioacyloxy, optionally substituted sulfinyl, optionally substituted sulfinylamino, optionally substituted sulfonyl, optionally substituted sulphonylamino, optionally substituted thio, optionally substituted thioacyl, optionally substituted thioacylamino, or optionally substituted thioacyloxy; or any of R.sup.2A and R.sup.2B, R.sup.2B and R.sup.2C, R.sup.2C and R.sup.2D, and R.sup.2D and R.sup.2E, together form an optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloalkenyl; and Q represents C.sub.1-4 alkyl. 6. The combination according to claim 5, wherein L is a carbonyl group (C.dbd.O), and at least one of R.sup.2D, R.sup.2C or R.sup.2B is a hydroxy or C.sub.1-3 alkoxy group. 7. The combination according to claim 5, wherein L is a carboxyl group (C.dbd.O), and R.sup.2D, R.sup.2C, and R.sup.2B are methoxy. 8. The combination according to claim 5, wherein L is a carbonyl group (C.dbd.O), R.sup.2D, R.sup.2C, and R.sup.2B are methoxy and R.sup.1A, R.sup.1B, R.sup.2A and R.sup.2E are H. 9. The combination according to claim 5, wherein L is a carbonyl group (C.dbd.O), R.sup.2D, R.sup.2C, and R.sup.2B are methoxy, R.sup.1A, R.sup.1B, R.sup.2A and R.sup.2E are H, and R.sup.1D is hydroxy. 10. The combination according to claim 1 wherein the at least one other cytotoxic compound is selected from the group consisting of 5-FU, oxaliplatin, paclitaxel, gemcitabine, docetaxel, cisplatin, and doxorubicin. 11. The combination according to claim 10 further including an angiogenesis inhibitor. 12. The combination according to claim 11 wherein the angiogenesis inhibitor is Avastin. 13. The combination according to claim 1 further including a radiopharmaceutical. 14. The combination according to claim 1 further including an antihypertensive or antihypotensive. 15. A method for inhibiting tubulin polymerisation comprising administering to a subject in need thereof the respective members of the combination of claim 1 together, one after the other, repeatedly in one combination dose or in separate unit dosage forms. 16. A pharmaceutical composition comprising the combination according to claim 1. 17. The method according to claim 15, wherein the subject has cancer that is selected from leukemias, melanomas, colon, lung, ovarian, skin, breast, prostate, CNS, and renal cancers, and wherein the compound of formula (I) is a compound of formula (Ib) ##STR00111## or a salt thereof, wherein X represents O; R.sup.1C represents methoxy; R.sup.1D represents hydroxyl or phosphate ester; and Q represents methyl. 18. The method according to claim 17, wherein the cancer is ovarian and the at least one other cytotoxic compound is gemcitabine. 19. The method according to claim 17, wherein the cancer is ovarian and the at least one other cytotoxic compound is cisplatin. 20. The method according to claim 17, wherein the cancer is ovarian and the at least one other cytotoxic compound is carboplatin. 21. The method according to claim 17, wherein the compound of formula (Ib) is ##STR00112##

Details for Patent 10,213,409

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2026-02-03